Skip to content

Rennova Health, Inc.

Delisted

CIK 931059fmd_1C9MWV2YQAEWZE0PNJPZ4ZX3E8Services · Services-General Medical & Surgical Hospitals, NECTemplate: Standard

Coverage: Jan 01, 2010 to Dec 31, 2023, 55 periods

Latest annual · FY2023

Millions
Total revenues
19
Gross profit
11
Operating income
1
Net income
(8)
Free cash flow
(0)

Latest quarter · Q4 FY2023

Millions
Total revenues
4
Gross profit
2
Operating income
(1)
Net income
(9)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2020 to FY2023
+37.5%
Revenue, 5 yearsFY2018 to FY2023
+5.1%
Net income, 5 yearsFY2018 to FY2023
n/m

Rennova Health, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2023FY2022ChangeSource
Revenue$18.7 million$13 million+43.8%10-K 2025-02-14 · proof
Gross profit$11.1 million$6.2 million+78.5%10-K 2025-02-14 · proof
Operating income$1.4 million-$1.4 million10-K 2025-02-14 · proof
Net income-$7.7 million-$3.3 million10-K 2025-02-14 · proof
Cash from operating activities$3.4 million-$218,34810-K 2025-02-14 · proof
Total assets$20.3 million$20.6 million-1.6%10-K 2025-02-14 · proof
Total liabilities$57.1 million$49.7 million+15%10-K 2025-02-14 · proof
Cash and cash equivalents$49,015$499,470-90.2%10-K 2025-02-14 · proof
Total debt$11.4 million$37.7 million-69.7%10-K 2025-02-14 · proof
What was Rennova Health, Inc.'s revenue in fiscal 2023?
Rennova Health, Inc. reported revenue of $18.7 million for fiscal 2023 (the year ended Dec 31, 2023), against $13 million the year before (+43.8%). Source: the 10-K filed with the SEC on Feb 14, 2025. SEC
What was Rennova Health, Inc.'s gross profit in fiscal 2023?
Rennova Health, Inc. reported gross profit of $11.1 million for fiscal 2023 (the year ended Dec 31, 2023), against $6.2 million the year before (+78.5%). Source: the 10-K filed with the SEC on Feb 14, 2025. SEC
What was Rennova Health, Inc.'s operating income in fiscal 2023?
Rennova Health, Inc. reported operating income of $1.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$1.4 million the year before. Source: the 10-K filed with the SEC on Feb 14, 2025. SEC
What was Rennova Health, Inc.'s net income in fiscal 2023?
Rennova Health, Inc. reported net income of -$7.7 million for fiscal 2023 (the year ended Dec 31, 2023), against -$3.3 million the year before. Source: the 10-K filed with the SEC on Feb 14, 2025. SEC
What was Rennova Health, Inc.'s cash from operating activities in fiscal 2023?
Rennova Health, Inc. reported cash from operating activities of $3.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$218,348 the year before. Source: the 10-K filed with the SEC on Feb 14, 2025. SEC
What are Rennova Health, Inc.'s total assets?
As of Dec 31, 2023, Rennova Health, Inc. reported total assets of $20.3 million, against $20.6 million a year earlier (-1.6%). Source: the 10-K filed with the SEC on Feb 14, 2025. SEC
What are Rennova Health, Inc.'s total liabilities?
As of Dec 31, 2023, Rennova Health, Inc. reported total liabilities of $57.1 million, against $49.7 million a year earlier (+15%). Source: the 10-K filed with the SEC on Feb 14, 2025. SEC
What are Rennova Health, Inc.'s cash and cash equivalents?
As of Dec 31, 2023, Rennova Health, Inc. reported cash and cash equivalents of $49,015, against $499,470 a year earlier (-90.2%). Source: the 10-K filed with the SEC on Feb 14, 2025. SEC
What is Rennova Health, Inc.'s total debt?
As of Dec 31, 2023, Rennova Health, Inc. reported total debt of $11.4 million, against $37.7 million a year earlier (-69.7%). Source: the 10-K filed with the SEC on Feb 14, 2025. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:931059&period_type=annual&limit=5"

Information only, not investment advice.